[PDF][PDF] Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t (4; 14), del (17p), 1q gains] play a major role in defining long-term survival
H Avet-Loiseau, M Attal, L Campion, D Caillot… - J Clin …, 2012 - researchgate.net
H Avet-Loiseau, M Attal, L Campion, D Caillot, C Hulin, G Marit, AM Stoppa, L Voillat…
J Clin Oncol, 2012•researchgate.netPurpose In multiple myeloma, many prognostic parameters have been proposed. However,
all of these predict shorter survival. To identify patients with a longer life expectancy, we
updated the data of patients treated in the IFM (Intergroupe Francophone du Myelome) 99-
02 and 99-04 trials.
all of these predict shorter survival. To identify patients with a longer life expectancy, we
updated the data of patients treated in the IFM (Intergroupe Francophone du Myelome) 99-
02 and 99-04 trials.
Purpose
In multiple myeloma, many prognostic parameters have been proposed. However, all of these predict shorter survival. To identify patients with a longer life expectancy, we updated the data of patients treated in the IFM (Intergroupe Francophone du Myelome) 99-02 and 99-04 trials.
researchgate.net